Omnicare sees FY12 adjusted EPS $3.30-$3.36, consensus $3.34 Sees FY12 revenue $6.1B-$6.2B, consensus $6.14B. Guidance reflects 14%-16% increase in adjusted cash-based EPS on y/y basis. Comments from slides that will be presented at the company's Analyst Day.
Omnicare, McKesson expand distribution agreement Omnicare (OCR) and McKesson Corporation (MCK) announced the signing of an expanded agreement to include the sourcing and distribution of branded, specialty and generic pharmaceuticals. The new five year agreement, which extends through December 2019, creates efficiencies for both companies by leveraging the strength of Omnicare as the nationís largest institutional pharmacy and a leading specialty pharmaceutical services provider and McKesson as a global leader in pharmaceutical sourcing and supply chain management. Omnicare noted that it believes the benefits of its new sourcing strategy will be a key driver in enabling it to generate a low double-digit adjusted cash EPS growth rate in 2015.